

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 020618-000600US
Client Reference No.: N9-59

On June 16, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Nicole Wartell
Nicole Wartell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory S. Hageman

Application No.: 09/511,008

Filed: February 22, 2000

For: DIAGNOSTICS AND
THERAPEUTICS FOR ARTERIAL
WALL DISRUPTIVE DISORDERS

Examiner: Q. Janice Li

Art Unit: 1632

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no



PTO/SB/21 (02-04)

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/511,008
	Filing Date	February 22, 2000
	First Named Inventor	Hageman, Gregory S.
	Art Unit	1632
	Examiner Name	Q. Janice Li
Total Number of Pages in This Submission	Attorney Docket Number	020618-000600US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of thirty-six (36) cited references
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Townsend and Townsend and Crew LLP Scott L. Auserhus Reg. No. 42,271	
Signature		
Date	6-16-04	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Nicole Wartell	
Signature		Date 6/16/04

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:nmb



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
			Application Number	09/511,008
			Filing Date	February 22, 2000
			First Named Inventor	Hageman, Gregory S.
			Art Unit	1632
Examiner Name	Q. Janice Li			
Sheet 1 of 4	Attorney Docket Number 020618-000600US			


U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				
	A2				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	PCT	WO 01/02866	A1	01-11-2001			<input type="checkbox"/>
	B2	PCT	WO 01/06262	A1	01-25-2001			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60227154 v1



Substitute for form PTO/SB/08B INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/511,008	
			Filing Date	February 22, 2000	
			First Named Inventor	Hageman, Gregory S.	
			Art Unit	1632	
			Examiner Name	Q. Janice Li	
Sheet	2	of	4	Attorney Docket Number	020618-000600US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ANIDJAR, S. et al. "Elastase-induced experimental aneurysms in rats" Circulation, Sept. 1990, pp. 973-981, Vol. 82, No. 3.	
	C2	Cobb et al. "Matrix Metalloproteinases and Their Inhibitors in Vitreous in Age-Related Macular Degeneration and Proliferative Diabetic Retinopathy" Investigative Ophthalmology and Visual Science Abstract Book- Part 1, March 1997, 1651 S354 Vol. 38, No. 4.	
	C3	COHEN, J.R. et al. "Role of the neutrophil in abdominal aortic aneurysm development" Cardiovasc. Surg., August 1993, pp. 373-376, Vol. 1, No. 4.	
	C4	COHEN, J.R. et al. "Urinary L-valyl proline in patients with aortic aneurysms" Surg. Gynecol. Obstet., June 1989, pp. 507-512, Vol. 168, No. 6.	
	C5	DEPALMA, R.G. et al. "Approaches to evaluating regression of experimental atherosclerosis" Adv. Exp. Med. Biol., 1977, pp. 459-470, Vol. 82.	
	C6	GINEITIS, A. et al. "Two-dimensional high-resolution electrophoresis of elastin-derived peptides" J. Chromatogr. B. Biomed. Sci. Appl., 9 May 1997, pp. 303-310, Vol. 692, No. 2.	
	C7	GOLDBERG, J. et al. "Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey" Am J. Epidemiol., Oct. 1988, pp. 700-710, Vol. 128, No. 4.	
	C8	HIRVELA, H. et al. "Risk factors of age-related maculopathy in a population 70 years of age or older" Ophthalmology, June 1996, pp. 871-877, Vol. 103, No. 6.	
	C9	HYMAN, L.G. et al. "Senile macular degeneration: a case-control study" Am. J. Epidemiol., August 1983, pp. 213-227, Vol. 118, No. 2.	
	C10	JUVONEN, T. et al. "Demonstration of a bioactive elastin-derived peptide (Val-Gly-Val-Ala-Pro-Gly) in vascular lesions characterized by the segmental destruction of media" Ann. Chir. Gynaecol., 1994, pp. 296-302, Vol. 83, No. 4.	
	C11	KLEIN, R. et al. "Early age-related maculopathy in the cardiovascular health study" Ophthalmology, Jan 2003, pp. 25-33, Vol. 110, No. 1.	
	C12	KLEIN, R. et al. "Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study" Arch. Ophthalmol., Sept, 1999, pp. 1203-1210, Vol. 117, No. 9.	
	C13	KLEIN, R. et al. "The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: the Beaver Dam Eye Study" Ophthalmology, Nov. 1997, pp. 1804-1812, Vol. 104, No. 11.	
	C14	KUIVANIEMI, H. et al. "Candidate genes for abdominal aortic aneurysms" Ann. NY Acad. Sci., Nov. 1996, pp. 186-197, Vol. 800.	
	C15	LINDHOLT, J.S. et al. "Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms" Eur. J. Vasc. Endovasc. Surg. July 1997, pp. 12-16, Vol. 14, No. 1.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/511,008	
			Filing Date	February 22, 2000	
			First Named Inventor	Hageman, Gregory S.	
			Art Unit	1632	
			Examiner Name	Q. Janice Li	
Sheet	3	of	4	Attorney Docket Number	020618-000600US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C16	LOUWRENS, H.D. et al. "Risk factors for the atherosclerosis in men with stenosing or aneurysmal disease of the abdominal aorta" Int. Angiol., March 1993, pp. 21-24, Vol. 12, No. 1.	
	C17	MACSWEENEY, S.T. et al. "Pathogenesis of abdominal aortic aneurysm" Br. J. Surg., July 1994, pp. 935-941, Vol. 81, No. 7.	
	C18	MALINOW, M.R. & MARUFFO, C.A. "Naturally occurring atherosclerosis in howler monkeys (Alouatta caraya)" J. Atheroscler. Res., Jul-Aug. 1966, pp. 368-380, Vol. 6, No. 4.	
	C19	NACKMAN, G.B. et al. "Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model" Surgery, July 1997, pp. 39-44, Vol. 122, No. 1.	
	C20	NORRGARD, O. et al. "Familial aortic aneurysms: serum concentrations of triglyceride, cholesterol, HDL-cholesterol and (VLDL + LDL)-cholesterol" Br. J. Surg., Feb. 1985, pp. 113-116, Vol. 72, No. 2.	
	C21	NORRGARD, O. et al. "High concentrations of Lp(a) lipoprotein in serum are common among patients with abdominal aortic aneurysms" Int. Angiol., Jan-March 1988, pp. 46-49, Vol. 7, No. 1.	
	C22	SMITH, W. et al. "Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study" Arch. Ophthalmol. May 1998, pp. 583-587, Vol. 116, No. 5.	
	C23	SMITH, W. et al. "Risk factors for age-related macular degeneration: Pooled findings from three continents" Ophthalmology, April 2001, pp. 697-704, Vol. 108, No. 4.	
	C24	SPERDUTO, R.D. & HILLER, R. "Systemic hypertension and age-related maculopathy in the Framingham study" Arch. Ophthalmol., Feb 1986, pp. 216-219, Vol. 104, No. 2.	
	C25	STRICKLAND, H.L. & BOND, M.G. "Aneurysms in a large colony of squirrel monkeys (Saimiri sciureus)" Lab Anim. Sci., Dec. 1983, pp. 589-592, Vol. 33, No. 6.	
	C26	Tarkkanen and Laatikainen, "Late ocular manifestations in neonatalherpes simplex infection," Br. J. Ophthalmol., vol. 61, pages 608-616, 1977.	
	C27	THOMPSON, R.W. "Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem" Curr. Opin. Cardiol., Sept. 1996, pp. 504-518, Vol. 11, No. 5.	
	C28	TILSON, M.D. & STANSEL, H.C. "Differences in results for aneurysm vs occlusive disease after bifurcation grafts: results of 100 elective grafts." Arch. Surg., Oct. 1980, pp. 1173-1175, Vol. 115, no. 10.	
	C29	TILSON, MD, & NEWMAN, K. "Rationale for molecular approaches to the etiology of abdominal aortic aneurysm disease" J. Vasc. Surg., May 1992, pp. 924-925, Vol. 15, No. 5.	
	C30	VERLOES, A. et al. "Genetic aspects of abdominal aortic aneurysm." Ann. NY Acad. Sci., 18 Nov. 1996, pp. 44-55, Vol. 800.	
	C31	VINDING, T. et al. "Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals" Acta. Ophthalmol., Feb. 1992, pp. 66-72, Vol. 70, No. 1.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			<i>Application Number</i>	09/511,008	
			<i>Filing Date</i>	February 22, 2000	
			<i>First Named Inventor</i>	Hageman, Gregory S.	
			<i>Art Unit</i>	1632	
			<i>Examiner Name</i>	Q. Janice Li	
Sheet	4	of	4	<i>Attorney Docket Number</i>	020618-000600US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C32	WILMINK, A.B. & QUICK, C.R. "Epidemiology and potential for prevention of abdominal aortic aneurysm" Br. J. Surg., Feb. 1998, pp. 155-162, Vol. 85, No. 2.	
	C33	ZARINS, C.K. et al. "Aneurysm formation in experimental atherosclerosis: relationship to plaque evolution" J. Vasc. Surg., 1990, pp. 246-256, Vol. 12.	
	C34	ZARINS, C.K. et al. "Aneurysmal enlargement of the aorta during regression of experimental atherosclerosis" J. Vasc. Surg., Jan 1992, pp. 90-101, Vol. 15, No. 1.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

JUN 18 2004



PTO/SB/17 (10-03)

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180

Complete if Known

Application Number 09/511,008
 Filing Date February 22, 2000
 First Named Inventor Hageman, Gregory S.
 Examiner Name Q. Janice Li
 Art Unit 1632
 Attorney Docket No. 020618-000600US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None
☒ Deposit Account:Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1001	770	2001 385 Utility filing fee	
		1002	340	2002 170 Design filing fee	
		1003	530	2003 265 Plant filing fee	
		1004	770	2004 385 Reissue filing fee	
		1005	160	2005 80 Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
	** =		
Independent Claims	** =		
Multiple Dependent	X		

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description
		1202	18	2202 9 Claims in excess of 20
		1201	86	2201 43 Independent claims in excess of 3
		1203	290	2203 145 Multiple dependent claim, if not paid
		1204	86	2204 43 ** Reissue independent claims over original patent
		1205	18	2205 9 ** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large	Entity	Small	Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

(\$180)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type) Scott L. Aussenhus Registration No. (Attorney/Agent) 42,271 Telephone 303-571-4000

Signature

Date

6-16-04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.